With Hong Kong’s aging population, Alzheimer’s disease has become a major public health challenge. The Hong Kong Council of Social Service projects that by 2036, the number of people with dementia in Hong Kong will reach 280,000. Alzheimer’s disease is the most common form of the condition, accounting for about 65% of existing cases among older adults.
A recent report by the dean of the Faculty of Chinese Medicine at a Hong Kong university stated: “Considerable resources have been invested globally in developing treatments for Alzheimer’s disease. However, for patients in the middle and late stages of the disease, various treatment options remain ineffective in halting its progression.”
These treatments not only have limited effectiveness, but also come with side effects, creating an increasingly urgent need for prevention and treatment.
In 2025, a collaboration between a research team at a leading Hong Kong university and Prof. Nick Wang, founder and head of R&D at eefit, led to a breakthrough. They found that eefit far-infrared technology can simultaneously suppress beta-amyloid (Aβ) deposition and tau protein hyperphosphorylation, offering a potential way to prevent Alzheimer’s disease. The results were published in NeuroMolecular Medicine (Vol. 27, Article 34, 2025).
First Study with Evidence of Simultaneous Dual-Pathology Improvement Mechanism in Transgenic Mouse Model
To address the future need for Alzheimer’s disease prevention and treatment in Hong Kong, the research team explored non-pharmacological physical therapies. Using a TgCRND8 transgenic mouse model, they conducted a 28-day irradiation experiment with eefit far infrared light (FIR, wavelength range of 4-20μm) to evaluate its effectiveness in improving disease pathology. The study found:
- Improved cognitive function: The FIR-treated mice group showed significant improvement in cognitive function and memory during the Morris water maze test (MWMT).
- Aβ deposition suppression: Decreased Aβ42/Aβ40 ratio in the cortex, reduced plaque deposits, and increased Aβ clearance.
- Tau protein hyperphosphorylation inhibition: Significantly reduced tau protein phosphorylation levels at different sites, such as Thr205, Ser36, etc., and reduced the formation of neurofibrillary tangles.
- Dual-pathway mechanism: Suppression of neuroinflammatory pathways (reduced IL-1β, TNF-α and increased IL-4) and activation of antioxidant pathways (enhanced Nrf2/HO-1 pathway), achieving dual-pathway protection.
Using a transgenic mouse model, this study confirms for the first time that eefit far infrared technology can simultaneously reduce Aβ deposition and tau protein hyperphosphorylation through physical intervention. Previous studies have only focused on single-pathology interventions, making the significance of this study on the dual-pathway improvement effect groundbreaking.
The dean of the Faculty of Chinese Medicine at a Hong Kong university said, “As a noninvasive treatment option, far-infrared therapy has the potential to delay disease progression in patients with mild cognitive impairment for several years, reducing the burden on medical resources and providing significant help to families and caregivers.”
This groundbreaking discovery also provides solid scientific evidence to support the industrial application of eefit far infrared technology.
International R&D Team Drives Industrialisation Capability
To promote the transformation of far-infrared technology from scientific research to industrial applications, eefit has built a global R&D system with research as its core driving force. In its early years, it collaborated with the State Key Laboratory of Quality Research in Chinese Medicine at the Macau University of Science and Technology to launch the eefit Biomedical Research Project.
In 2021, eefit expanded its global collaboration network by partnering with Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, founded by Dr. Erwin Neher, Nobel Prize laureate in physiology or medicine, further strengthening its R&D capability.
In recent years, multiple international journal articles have confirmed that eefit far infrared technology is effective in the fields of intestinal microecology, rheumatoid arthritis, cerebral stroke, neuroinflammation, and immunomodulation.
Market Response and Social Responsibility Are Equally Important
In tandem with advancing scientific research, eefit is also committed to upholding its social responsibilities. In 2024, eefit launched the eBrain Movement, which provided brain health services to 212,000 people across its retail stores in Hong Kong.
User feedback showed improvements in conditions including headaches, tinnitus, hair loss, hand tremors, and nocturia, with unanimous reports of better sleep quality after treatment. Both this program and academic research have demonstrated the effect of eefit far-infrared technology in brain health, subhealth in middle-aged and older adults, and as an auxiliary treatment for complex diseases.
Multidimensional Breakthrough in Managing Sub-Health in the Middle-Aged and Elderly
Based on this technology, eefit has already developed a variety of products, building an all-encompassing “Prevention + Maintenance + Adjustment” health management system, meeting the diverse needs of the middle-aged and elderly population from disease prevention to daily health management:
- Alzheimer’s disease prevention: Reduces Aβ deposits and abnormal tau proteins, reducing the risk of disease.
- Brain health: Relieves neurological problems such as effects of stroke, and enhances brain vitality.
- Chronic pain care: Relieves pains such as neck/shoulder/lower back/leg pain, and rheumatoid arthritis, etc.
- Digestive system regulation: Optimizes gut microbiota and enhances nutrient absorption.
About eefit
Based in Hong Kong, eefit has services available throughout the city. With leading service coverage and an innovative product matrix, we provide customers with convenient and efficient health management solutions. This Alzheimer’s disease pathology improvement study further verifies that eefit far infrared technology can put scientific research into practice in daily life. eefit is committed to ongoing investment in technological R&D to propel the advancement and innovation in health technology. For more information, visit www.eefit.com.
Media Contact
Nicole Gao
nicole.gao@eefit.com
